Company Overview - Zhan Yan Biotechnology Co., Ltd. was established on December 6, 2019, with a registered capital of 61.62 million yuan and is located in Chengdu, Sichuan, China [1] - The company is primarily engaged in the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The controlling shareholder is Zhang Yingting, who directly holds 62.1551% of the company's shares [1] IPO and Financial Performance - Zhan Yan Biotechnology has completed its IPO counseling registration with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange [1] - The company aims to be listed on the New Third Board by September 2025 [1] - Projected revenues for 2023 and 2024 are 486 million yuan and 597 million yuan, respectively, with net profits of 68.48 million yuan and 73.50 million yuan [2][3] - The gross profit margins for 2023 and 2024 are expected to be 62.33% and 68.34%, respectively [2][3] Shareholding Structure - As of the date of the public transfer prospectus, Zhang Yingting directly holds 62.16% of the shares and, through concerted actions, controls 91.22% of the voting rights [3] - Other shareholders include Yang Fengle, who holds 17.79%, and Hengqin Zhan Yan, an employee stock ownership platform, which holds 11.28% [3] - Wang Kun directly holds 4.06% and indirectly holds 0.24%, while Tax Ke Ying directly holds 0.41% and indirectly holds 0.31% [4] Management Team - Zhang Yingting serves as the Chairman and Manager of the company [5] - Wang Kun is the Director and Deputy Manager, while Tax Ke Ying is the Secretary of the Board and Chief Financial Officer [5] - The management team has extensive experience in the pharmaceutical and biotechnology sectors, with backgrounds in various companies prior to joining Zhan Yan Biotechnology [6][7][8]

Group 1 - The core viewpoint of the news is that Zhan Yan Biotechnology Co., Ltd. has completed its IPO counseling record with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange, with China International Capital Corporation as the counseling institution [1] - Zhan Yan Biotechnology was established on December 6, 2019, with a registered capital of 61.62 million yuan, focusing on the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The company has three major sub-brands: "Zhan Yan" for skin issues, "Zhan Xiao Yan" for infant skincare, and "De Fei Lin" for bioactive composite acids, targeting different demographics with product lines for skin disease auxiliary treatment and sensitive skin repair [2] Group 2 - The projected operating revenue for Zhan Yan Biotechnology is 486 million yuan in 2023 and 597 million yuan in 2024, with net profits of 68.48 million yuan and 73.50 million yuan respectively, and gross profit margins of 62.33% and 68.34% [2][3] - In 2024, the company expects to achieve an operating revenue of 597.47 million yuan and a net profit of 73.50 million yuan, with a gross profit margin of 68.34% and a weighted return on net assets of 22.39% [3] - Zhang Yingting, the controlling shareholder, directly holds 62.16% of the company's shares and, along with his associates, controls 91.22% of the voting rights [3]

Group 1 - The core viewpoint of the article is that Zhan Yan Biotechnology Co., Ltd. has initiated the listing guidance process with the support of China International Capital Corporation [1] - Zhan Yan Biotechnology was established on December 6, 2019, with a registered capital of 61.62 million yuan [1] - The legal representative of the company is Zhang Yingting, who is also the controlling shareholder, holding 62.1551% of the company's equity [1] Group 2 - The company specializes in the research, production, and sales of biomedical materials, dermatological skincare products, and biological raw materials [1] - Zhan Yan has developed several brands, including the dermatological repair brand Zhan Yan, the infant skincare brand Zhan Xiao Yan, and the brand Defilin [1]